Homepage

Terms of Use

About Us

• Management Team
• Board of Directors
• Personalized Medicine

Products

• OMAPRO™ (omacetaxine mepesuccinate)
• Quinamed® (amonafide dihydrochloride)

Research and Development

• Drug Discovery & Preclinical Development
• Genomic Clinical Development

Investors

• Financial Reports
• Presentations
• Corporate Governance
• Analyst Coverage
• Information Requests

News, Media & Events

• Recent Press Releases
• Press Release Archive
  • 2009 Press Releases
  • 2008 Press Releases
  • 2007 Press Releases
  • 2006 Press Release
• Media Contact

Clinical Trials

• Chronic Myelogenous Leukemia
  • Omacetaxine mepesuccinate in Multi-TKI Resistant Patients
  • Omacetaxine mepesuccinate +T315I Mutation
  • Omacetaxine mepesuccinate plus imatinib mesylate
• Myelodysplastic Syndrome
  • Omacetaxine mepesuccinate
• Solid Cancers
  • Amonafide Dihydrochloride (Quinamed®)

Careers

• Culture
• Current Openings

Contact us

Home Contact Us Sitemap

© 2010 ChemGenex Pharmaceuticals

Terms of Use